What are unapproved peptides and how are they different from TGA-approved medicines?

Unapproved therapeutic goods are products that have not been evaluated by the Therapeutic Goods Administration (TGA) for safety, quality, and efficacy in Australia. Some peptide compounds are used for muscle building, injury recovery, or aesthetic purposes and are prescribed outside the standard approval pathway — either through the Special Access Scheme or by compounding pharmacies. This means there is no independent regulatory guarantee that they are safe or effective for the purpose being claimed. TGA-approved medicines have passed a defined evidence review; unapproved medicines have not.

Can a doctor in Australia legally prescribe an unapproved medicine?

Yes, under specific circumstances. The TGA's Special Access Scheme (SAS) allows doctors to prescribe unapproved therapeutic goods in individual cases where the potential benefit justifies the risk and appropriate consent is given. The Medical Board's concern is about scale: prescribing unapproved medicines to large numbers of patients via brief telehealth encounters, without adequate clinical assessment or follow-up, is what the Board considers potentially inappropriate. The Board is not saying the medicines are categorically off-limits; it is saying the current prescribing pattern does not meet the standard of care expected.

Medical Board warns on telehealth peptide prescribing at scale

What just happened

Australia’s Medical Board chair, Dr Susan O’Dwyer, has issued a public warning that doctors prescribing unapproved peptides through telehealth services — at scale, without adequate clinical assessment — risk bringing the profession into disrepute. The concern, reported by AusDoc on 13 August 2026, centres on peptide compounds prescribed primarily for aesthetic and performance purposes: muscle building, body composition, and injury recovery claims that sit outside the standard TGA-approval framework.

This is the second regulatory intervention in 12 months. In July 2025, the Board issued guidance on medicinal cannabis after similar patterns emerged — rapid telehealth consultations, minimal assessment, high prescribing volumes. Following that guidance, medicinal cannabis prescribing dropped by 30% within six months. The Board is now developing equivalent guidance for unapproved peptides.

The professional intervention makes sense on its own terms. But for patients who have been prescribed these compounds — or who are thinking about it — the question is simpler and harder: what does this mean for me?

Both-and

What the Board is actually saying

The Medical Board’s concern is not that unapproved medicines are categorically illegitimate. The TGA’s Special Access Scheme (SAS) exists precisely to allow doctors to prescribe products that have not completed full approval — in cases where the clinical rationale justifies the risk and the patient is appropriately informed. That pathway is legal, regulated, and sometimes clinically appropriate.

What the Board is flagging is the pattern: large-volume prescribing through short telehealth encounters, primarily for cosmetic or performance purposes, without the individual clinical assessment that should accompany a decision to use an unapproved good. Under the Medical Board’s prescribing standards, prescribing an unapproved medicine requires that a doctor satisfy themselves — through adequate assessment — that the benefit justifies the risk for that specific patient. Brief, template-driven telehealth encounters may not meet that standard.

The Board’s comparison to the medicinal cannabis intervention is deliberate. That warning produced a 30% reduction in prescribing volume — a signal that a significant proportion of prior prescribing was occurring at the threshold of appropriateness, and that professional accountability pressure shifted behaviour quickly.

What patients are actually navigating

The context for this intervention is the weight-loss and wellness boom that has accelerated alongside GLP-1 receptor agonist availability. As Ozempic and Wegovy have gained cultural traction — and remained expensive out-of-pocket — some patients have turned to telehealth providers offering alternative compounds with weight-loss or body-composition claims. These include various unapproved peptide products, some available through compounding pharmacies.

This is not an abstract regulatory problem. Many patients have been let down by the mainstream system: dismissed when asking about weight, told to try harder, given advice that didn’t hold. When a telehealth provider offers something that feels like a solution — with minimal friction and a confident clinical framing — the appeal is understandable. The Medical Board’s intervention does not resolve the underlying failure that created the demand.

It does, however, signal that the prescribing environment is about to tighten. Practices that have operated under minimal regulatory scrutiny are likely to be the subject of the same kind of guidance that restructured the medicinal cannabis prescribing market last year.

The evidence problem

The core issue with unapproved peptides is not that they are definitely harmful — the evidence base is simply insufficient to say either way for most compounds in this space. They have not gone through the TGA’s evaluation process. There are no large randomised controlled trials. The safety signals that would emerge from post-market surveillance of an approved medicine do not exist for compounds that have never been formally registered. This is a genuine epistemic problem for anyone — patient or doctor — trying to make an informed decision.

That uncertainty is not an endorsement of a blanket ban. It is an argument for careful individual clinical assessment, rather than volume prescribing through low-touch encounters.

My two cents

If you have been prescribed an unapproved peptide through a telehealth service, it is worth understanding exactly what you have been given and what the evidence basis is — which means a conversation with your regular GP who has your full clinical history in front of them. That is not a statement about the honesty of the telehealth provider. It is a statement about the value of clinical continuity.

The broader pattern here is worth watching. The weight-loss and wellness telehealth market in Australia has grown rapidly, and regulatory guidance typically follows practice rather than preceding it. The medicinal cannabis precedent suggests that when guidance arrives, it arrives with real force: a 30% prescribing reduction in six months is not a small adjustment.

For anyone currently using one of these compounds: the Board’s intervention does not require immediate action on your part. But it does mean that the prescribing environment may look different in six months, and that any discussion with a telehealth provider about continuing or starting treatment is worth also having with a GP who knows you.

Verdict: yes — the regulatory signal matters, and the underlying evidence question about unapproved peptides is one every patient using them deserves to understand.

Sources cited

Medical board chair issues warning to telehealth doctors prescribing unapproved drugs. AusDoc, 13 August 2026. https://www.ausdoc.com.au/news/are-they-bringing-the-profession-into-disrepute-medical-board-chair-on-the-doctors-prescribing-unapproved-drugs-at-scale/
Medical Board of Australia — prescribing responsibilities. https://www.medicalboard.gov.au/Codes-Guidelines-Policies/Policies/Prescribing-responsibilities.aspx
TGA — guidance on use of unregistered therapeutic goods. https://www.tga.gov.au/resources/resource/guidance/guidance-use-unregistered-therapeutic-goods